세계의 유전자 도입 기술 시장 : 제품별, 모드별, 방법별, 용도별, 지역별 - 예측(-2029년)

The global gene transfer technologies market is projected to surpass USD 5.93 billion in 2029 from USD 3.73 billion in 2024, with a significant CAGR of 9.7%. Increasing demand for personalized medicines, along with advancements in cell and gene therapies, continues to grow and contribute to a rise in this market. In addition, the increased application of gene transfer technologies in vaccine development and cancer immunotherapy boosts the segmental growth.

"The viral vector gene transfer technologies segment accounted for the largest share in 2023."

On the basis of mode, the gene transfer technologies market is further segmented into viral vector and non-viral vector. The viral vector segment is retrovirus, adenovirus, adeno associated virus (AAV) and other virus vector. The viral vector segment dominated the market in 2023, owing to superior safety and efficacy profile, minimal immunogenicity and advancements in AAV engineering.

"By application, the therapeutic application segment accounted for the largest share in the gene transfer technologies market."

The application segment in the gene transfer technologies market is segmented into research application, therapeutic application and applications. The research application is segmented into drug discovery & development and other research application. Similarly the therapeutic application further divided into gene therapy, cell therapy, vaccines and other therapeutic application. The therapeutic application dominated the segment owing to advancements in gene transfer technologies, such as improved adeno-associated virus (AAV) & lentiviral vector and expanding application of gene therapy in cardiovascular, neurological and metabolic diseases.

"North America: the largest share of the gene transfer technologies market"

By region, the market is segment into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America dominated the gene transfer technologies market in 2023 and likely continue dominance during the forecast period. Presence of dominant market players in gene transfer technologies companies in the region, strong base of gene transfer technologies manufacturers such as Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany) are some of the prominent factors acerating market growth.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the gene transfer technologies market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany), Bio-Rad Laboratories Inc. (US), Revvity (US), Agilent Technologies, Inc. (US), Genscript (US), Bio-Techne (US), Lonza (Switzerland), Takara Bio, Inc. (Japan), Promega Corporation (US), Oxford Biomedica plc (UK) and MaxCyte (US) ) are some of the major players operating in the gene transfer technologies market.

Research Coverage:

This research report categorizes the gene transfer technologiess market product (instruments, consumables, reagents,kits & assays and other products), mode (viral vector and non viral vector), method (ex vivo, in vivo and in vitro), application (research, therapeutic and orther application) end user (pharmaceutical & biotechnology companies, academic & research institutes and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the gene transfer technologiess market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the gene transfer technologies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the gene transfer technologies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing demand for personalized medicines and cell & gene therapies, Increased investments in gene therapy research, Expanding applications in vaccine development & cancer immunotherapy), restraints (High costs of gene transfer systems), opportunities (Advancements in gene editing technologies and nanotechnology, Integration with digital technologies such as AI and ML) and Challenges (Scalability of production).
• Product Development/Innovation: Detailed insights on maintaining a comprehensive and innovative product portfolio offering for gene transfer technologies.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the gene transfer technologies market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany) and among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 MARKET ESTIMATION
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.3 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE PROJECTION
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 GENE DELIVERY TECHNOLOGIES MARKET OVERVIEW
• 4.2 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION (2023)
• 4.3 GENE DELIVERY TECHNOLOGIES MARKET SHARE, BY MODE, 2024 VS. 2029
• 4.4 GENE DELIVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing demand for personalized medicine and cell & gene therapies
    • 5.2.1.2 Increased investments in gene therapy research
    • 5.2.1.3 Expanding applications in vaccine development & cancer immunotherapy
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High costs of gene delivery systems
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Advancements in gene editing technologies & nanotechnology
    • 5.2.3.2 Integration with digital technologies such as AI & ML
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Scalability of production
• 5.3 ECOSYSTEM ANALYSIS
  • 5.3.1 PRODUCT PROVIDERS
  • 5.3.2 END USERS
  • 5.3.3 REGULATORY BODIES
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Microinjection
    • 5.4.1.2 Electroporation
    • 5.4.1.3 Sonoporation
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Gene editing technologies
    • 5.4.2.2 Bioinformatics and computational tools
  • 5.4.3 ADJCENT TECHNOLOGIES
    • 5.4.3.1 Nanotechnology and nano-carriers
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND OF REAGENTS/CONSUMABLES, BY KEY PLAYER
  • 5.5.2 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 SUPPLY CHAIN ANALYSIS
• 5.8 PATENT ANALYSIS
• 5.9 TRADE ANALYSIS
  • 5.9.1 IMPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330)
  • 5.9.2 EXPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330)
• 5.10 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.11 REGULATORY LANDSCAPE
  • 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11.2 REGULATORY FRAMEWORK
    • 5.11.2.1 North America
    • 5.11.2.2 Europe
    • 5.11.2.3 Asia Pacific
    • 5.11.2.4 Rest of the World
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 THREAT OF NEW ENTRANTS
  • 5.12.2 THREAT OF SUBSTITUTES
  • 5.12.3 BARGAINING POWER OF BUYERS
  • 5.12.4 BARGAINING POWER OF SUPPLIERS
  • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS
  • 5.13.2 BUYING CRITERIA
• 5.14 INVESTMENT AND FUNDING SCENARIO
• 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.16 IMPACT OF AI/GEN AI ON GENE DELIVERY TECHNOLOGIES MARKET

6 GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 REAGENTS, KITS, AND ASSAYS
  • 6.2.1 INCREASING DEMAND FOR TRANSFECTION AND GENE EDITING TOOLS TO DRIVE MARKET GROWTH
• 6.3 CONSUMABLES
  • 6.3.1 RISING R&D ACTIVITY TO SUPPORT DEMAND GROWTH
• 6.4 INSTRUMENTS
  • 6.4.1 INCREASING ADOPTION OF ELECTROPORATION DEVICES TO DRIVE MARKET
• 6.5 OTHER PRODUCTS

7 GENE DELIVERY TECHNOLOGIES MARKET, BY MODE

• 7.1 INTRODUCTION
• 7.2 VIRAL VECTORS
  • 7.2.1 RETROVIRUSES
    • 7.2.1.1 Lentiviruses
      • 7.2.1.1.1 Rising disease incidence to drive market
    • 7.2.1.2 Other retroviruses
  • 7.2.2 ADENOVIRUSES
    • 7.2.2.1 Expansion of vaccination programs to propel market growth
  • 7.2.3 ADENO-ASSOCIATED VIRUSES
    • 7.2.3.1 Low immunogenicity of AAV vectors to support adoption
  • 7.2.4 OTHER VIRAL VECTORS
• 7.3 NON-VIRAL VECTORS
  • 7.3.1 CHEMICAL METHODS
  • 7.3.2 LIPOSOME-MEDIATED
    • 7.3.2.1 High efficiency and compatibility to drive market
  • 7.3.3 CALCIUM PHOSPHATE
    • 7.3.3.1 Increasing R&D in cell-based therapies to propel market growth
  • 7.3.4 DEAE-DEXTRAN
    • 7.3.4.1 Simplicity and cost-effectiveness to support adoption
  • 7.3.5 CATIONIC POLYMERS
    • 7.3.5.1 Advancements in cationic polymer technology to drive market
  • 7.3.6 OTHER CHEMICAL METHODS
• 7.4 PHYSICAL METHODS
  • 7.4.1 ELECTROPORATION
    • 7.4.1.1 Rising demand for effective cell transfection technologies to drive market
  • 7.4.2 MICROINJECTION
    • 7.4.2.1 High accuracy and control and potential for tailored delivery to drive market
  • 7.4.3 GENE GUNS
    • 7.4.3.1 High efficiency of gene guns in transfecting various cell types to drive market
  • 7.4.4 OTHER PHYSICAL METHODS

8 GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD

• 8.1 INTRODUCTION
• 8.2 IN VIVO
  • 8.2.1 EMERGENCE OF MRNA-BASED VACCINES TO PROPEL IN VIVO GENE DELIVERY APPLICATIONS
• 8.3 EX VIVO
  • 8.3.1 SUCCESSFUL COMMERCIALIZATION OF CAR T-CELL THERAPIES TO DRIVE THE EX VIVO GENE DELIVERY MARKET
• 8.4 IN VITRO
  • 8.4.1 DATABASES MAJORLY CONTRIBUTE TO STORING GENE DELIVERY TECHNOLOGIES AND INTEGRATING OTHER OMICS DATABASES.

9 GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 THERAPEUTIC APPLICATIONS
  • 9.2.1 GENE THERAPY
    • 9.2.1.1 Increasing demand for personalized medicine to support market growth
  • 9.2.2 CELL THERAPY
    • 9.2.2.1 Rising government funding to propel market growth
  • 9.2.3 VACCINES
    • 9.2.3.1 Rising prevalence of infectious diseases to drive market growth
  • 9.2.4 OTHER THERAPEUTIC APPLICATIONS
• 9.3 RESEARCH APPLICATIONS
  • 9.3.1 DRUG DISCOVERY & DEVELOPMENT
    • 9.3.1.1 Increased funding for gene therapy research to drive market growth
    • 9.3.1.2 Cancer
      • 9.3.1.2.1 Rising investment in cancer research to drive market
  • 9.3.2 INFECTIOUS DISEASES
    • 9.3.2.1 Rising incidence of infectious disease to drive market growth
  • 9.3.3 GENETIC & NEUROLOGICAL DISORDERS
    • 9.3.3.1 Rising burden of disorders to drive market
  • 9.3.4 AUTOIMMUNE DISEASES
    • 9.3.4.1 Growing prevalence of autoimmune disorders to ensure demand for therapeutic solutions
  • 9.3.5 OTHER DISEASES
  • 9.3.6 OTHER RESEARCH APPLICATIONS
• 9.4 OTHER APPLICATIONS

10 GENE DELIVERY TECHNOLOGIES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE MARKET
• 10.3 ACADEMIC & RESEARCH INSTITUTES
  • 10.3.1 INCREASING R&D AND GROWING FUNDING AND PARTNERSHIPS TO PROMOTE MARKET GROWTH
• 10.4 OTHER END USERS

11 GENE DELIVERY TECHNOLOGIES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 11.2.2 US
    • 11.2.2.1 US to dominate North American market over forecast period
  • 11.2.3 CANADA
    • 11.2.3.1 Strong infrastructure and availability of funding for biomedical research to support market growth
• 11.3 EUROPE
  • 11.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 11.3.2 GERMANY
    • 11.3.2.1 Germany to hold largest market share in Europe
  • 11.3.3 UK
    • 11.3.3.1 Increasing government funding to drive market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Rising support for genetic research to offer potential growth opportunities
  • 11.3.5 ITALY
    • 11.3.5.1 Rising R&D and support for gene delivery to drive market
  • 11.3.6 SPAIN
    • 11.3.6.1 Growing expansion of research centers to stimulate market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 11.4.2 CHINA
    • 11.4.2.1 Increasing R&D expenditure to drive market growth
  • 11.4.3 JAPAN
    • 11.4.3.1 Rising research into precision medicine to support market growth
  • 11.4.4 INDIA
    • 11.4.4.1 Strong research base and rising FDI in pharma sector to support market growth
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 Alliances & investments in research to drive market
  • 11.4.6 AUSTRALIA
    • 11.4.6.1 Increasing focus on precision medicine to offer significant growth opportunities
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 11.5.2 BRAZIL
    • 11.5.2.1 Brazil to hold largest market share in LATAM
  • 11.5.3 MEXICO
    • 11.5.3.1 Strong pharmaceutical industry and increased government support to augment market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Saudi Arabia
      • 11.6.2.1.1 Increasing government investments in healthcare and growing pharmaceuticals industry to support market
    • 11.6.2.2 UAE
      • 11.6.2.2.1 Growing R&D expenditure and infrastructural development to drive market
    • 11.6.2.3 Rest of GCC Countries
  • 11.6.3 REST OF MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 RISING EMPHASIS ON GENE DELIVERY TECHNOLOGIES FOR THERAPEUTICS TO SUPPORT MARKET GROWTH
  • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GENE DELIVERY TECHNOLOGIES MARKET
• 12.3 REVENUE ANALYSIS
• 12.4 MARKET SHARE ANALYSIS
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product footprint
    • 12.5.5.4 Method footprint
    • 12.5.5.5 Application footprint
    • 12.5.5.6 End-user footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 THERMO FISHER SCIENTIFIC INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services/Solutions offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches
      • 13.1.1.3.2 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 DANAHER CORPORATION
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services/Solutions offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches
      • 13.1.2.3.2 Deals
      • 13.1.2.3.3 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 MERCK KGAA
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services/Solutions offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
      • 13.1.3.3.2 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 BIO-RAD LABORATORIES, INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services/Solutions offered
  • 13.1.5 AGILENT TECHNOLOGIES, INC.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services/Solutions offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
  • 13.1.6 REVVITY
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services/Solutions offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches
      • 13.1.6.3.2 Deals
  • 13.1.7 QIAGEN
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services/Solutions offered
  • 13.1.8 GENSCRIPT
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services/Solutions offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Deals
  • 13.1.9 TAKARA BIO INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services/Solutions offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches
      • 13.1.9.3.2 Deals
  • 13.1.10 PROMEGA CORPORATION
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services/Solutions offered
  • 13.1.11 BIO-TECHNE
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/Services/Solutions offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product launches
  • 13.1.12 LONZA
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services/Solutions offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches
      • 13.1.12.3.2 Deals
  • 13.1.13 OXFORD BIOMEDICA PLC
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products/Services/Solutions offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product launches
      • 13.1.13.3.2 Deals
      • 13.1.13.3.3 Other developments
  • 13.1.14 SARTORIUS AG
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products/Services/Solutions offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product launches
      • 13.1.14.3.2 Deals
  • 13.1.15 MAXCYTE
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products/Services/Solutions offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Deals
• 13.2 OTHER PLAYERS
  • 13.2.1 CELL BIOLABS, INC.
  • 13.2.2 GENTARGET INC.
  • 13.2.3 ORIGENE TECHNOLOGIES, INC.
  • 13.2.4 ALTOGEN BIOSYSTEMS
  • 13.2.5 OZ BIOSCIENCES
  • 13.2.6 GENECOPOEIA, INC.
  • 13.2.7 CREATIVE BIOLABS
  • 13.2.8 SYNBIO TECHNOLOGIES LLC
  • 13.2.9 SYSTEM BIOSCIENCES, LLC
  • 13.2.10 VECTORBUILDER INC.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS